[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nutritional-deficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nutritional-deficiency":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,46,79,121,155,179,208,236,265,291,315,347,369,405],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100635601","phase-3-a-randomized-double-blind-placebo-controlled-prospective-multi-center-trial-evaluating-the-improvement-of-nutritional-status-and-sarcopenia-with-silkworm-pupa-tablets-in-patients-with-malignancies-100635601",false,"NCT07554807","A Randomized, Double-blind, Placebo-controlled, Prospective, Multi-center Trial Evaluating the Improvement of Nutritional Status and Sarcopenia With Silkworm Pupa Tablets in Patients With Malignancies","Inclusion Criteria:\n\n1. fully understand and sign the Informed Consent Form (ICF); willing to follow and able to complete all trial procedures\n2. Any gender, age at ICF signing: ≥ 18 years, ≤ 80 years\n3. Confirmed diagnosis of malignancy\n4. At screening\u002F enrollment, meet the definition of sarcopenia according to the 2019 Asian Working Group for Sarcopenia\n5. Generally good condition, ECOG performance status ≤ 2\n6. Agree to provide peripheral blood, stool, and urine samples for biomarker analysis during the study\n\nExclusion Criteria:\n\n1. Presence of gastrointestinal obstruction preventing oral intake at screening\u002Fenrollment\n2. Use of immunosuppressants at screening\u002Fenrollment\n3. Life expectancy ≤ 3 months\n4. Presence of malabsorption syndrome or any condition affecting gastrointestinal absorption, e.g., chronic diarrhea (watery stools; daily stool frequency ≥ 5 times)\n5. Patients planning pregnancy, pregnant, or breastfeeding\n6. Known allergy to any component of the investigational products\n7. Presence of severe primary diseases of the heart, brain, lung, liver, kidney, endocrine, blood, nervous systems or other acute\u002Fchronic diseases that could significantly affect treatment and prognosis\n8. Presence of other severe physical or mental illnesses or laboratory abnormalities that may increase the risk of participating in the study, or patients deemed unsuitable for the study by the investigator","ALL","18 Years","80 Years",{"count":19,"type":20},480,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This is a randomized, double-blind, placebo-controlled, parallel-group, prospective, multi-center clinical trial, to evaluate the efficacy of silkworm pupa tablets in improving nutritional status and sarcopenia in patients with malignancies who have completed comprehensive treatment. All participants will be randomly assigned (1:1) to either experimental group (n=240): dietary advice + Wanshili Longbao Silkworm Pupa Tablets (main ingredients: freeze-dried active mulberry cocoon pupa powder, maltitol, milk mineral salt, mannitol, maltodextrin), 2 tablets three times daily before meals for 3 months, or control group (n=240): dietary advice + placebo (identical appearance), 2 tablets three times daily before meals for 3 months. The primary endpoint is sarcopenia prevalence at 3 months (based on AWGS 2019 criteria: muscle strength, muscle mass, and physical function).",[26,27,28],"Nutritional Deficiency","Gastrointestinal Cancers","Sarcopenia",[30,31,32],"silkworm pupa tablets","gastrointestinal malignancies","nutritional risk","NOT_YET_RECRUITING","2026-04-21",{"date":36,"type":37},"2026-04-28","ACTUAL",{"date":39,"type":20},"2026-04-01",{"date":41,"type":20},"2028-03-31",{"name":43,"class":44},"First Affiliated Hospital of Zhejiang University","OTHER",4,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100509320","the-effect-of-high-caloric-oral-nutritional-supplements-on-growth-and-development-of-malnourished-children-100509320","NCT05911893","the Effect of High Caloric Oral Nutritional Supplements on Growth and Development of Malnourished Children","EHCONSGDMC","Inclusion Criteria:\n\n* Aged 1-3 years\n* BMI for Age Z-score\\\u003C-2\n* Height-for-age z score\\\u003C-2\n* Total daily energy intake\\\u003C75% of recommended nutrient intake\n* The child's guardian is willing to participate in this study and sign an informed consent form.\n\nExclusion Criteria:\n\n* Chronic or severe infectious disease (e.g., chronic hepatitis, HIV or tuberculosis infection)\n* Certain congenital or genetic diseases affecting physical growth and development (congenital heart disease, Down's syndrome, infantile anorexia nervosa, etc.), malignancies and use of drugs (diuretics, appetite stimulants, steroids and growth hormones, etc.)\n* Severe gastrointestinal disorders (e.g., celiac disease, short bowel syndrome, inflammatory bowel disease, etc.)\n* Acute and chronic respiratory\u002Fdigestive tract infections within 2 weeks prior to enrollment\n* Allergy or contraindication to any of the ingredients in the high-energy total nutrition formula used in this study\n* Have used high-energy enteral nutrition preparations for the last 3 months","1 Year","3 Years",{"count":56,"type":20},200,[58],"NA","The goal of this clinical trial is to investigate the effect of high caloric oral nutritional supplements on body proportion, weight, linear growth pattern, neuropsychological development level and related health aspects (gut health, immune function, quality of life, etc.) in participants aged 1 to 3 years who are malnourished (underweight and wasting),as well as to evaluate the safety of applying high caloric oral nutritional supplements. Participants will receive nutritional education and daily high caloric oral nutritional supplements(experimental group),or will receive nutritional education and dietary instruction(control group).This study may provide data to support the development of clinical intervention strategies for malnourished Chinese children.",[61,62,26,63],"Malnutrition, Child","Malnourishment","Undernutrition",[65,66,67],"Oral Nutritional Supplements","Physique Growth","Neuropsychological Development","RECRUITING","2026-03-16",{"date":71,"type":37},"2026-03-18",{"date":73,"type":37},"2024-06-17",{"date":75,"type":20},"2026-03-10",{"name":77,"class":44},"Children's Hospital of Chongqing Medical University",13,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":90,"conditions":91,"keywords":105,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":120},"100596191","the-florida-ascent-study-100596191","NCT07042243","The Florida ASCENT Study","The Florida Partnership for Adding Social Context to Address Cancer Survivorship Outcomes (Florida ASCENT)","Patient Eligibility Inclusion Criteria:\n\n1. ≥18 years old.\n2. Pathologically confirmed diagnosis of colorectal, prostate, lung, breast, gynecologic, hematologic, or skin (including melanoma) cancer within the past 12 months.\n3. Self-reported ability to read and speak English.\n4. Able to provide informed consent.\n5. Participant must not be considered a \"vulnerable population\" (pregnant women, neonates, children etc.)\n\nPatient Eligibility Exclusion Criteria:\n\n1. ≤18 years old.\n2. Participant do not have a pathologically confirmed diagnosis of colorectal, prostate, lung, breast, gynecologic, hematologic, or skin (including melanoma) cancer within the past 12 months.\n3. Participant does not live within the state of Florida.\n\n3\\) Does not self-reported ability to read and speak English or Spanish. 4) Not able to provide informed consent. 5) Participant is considered a \"vulnerable population\" (pregnant women, neonates, children etc.)\n\nProvider Eligibility Inclusion Criteria\n\n1. ≥18 years old.\n2. Currently works as a physician, physician assistant, patient navigator and\u002For health system\u002Fadministrative leader in UF and UM affiliated clinics.\n3. Self-reported ability to read and speak English or Spanish.\n4. Able to provide informed consent.\n5. Participant must not be considered a \"vulnerable population\" (pregnant women, neonates, children etc.)\n\nProvider Eligibility Exclusion Criteria\n\n1. ≤ 18 years old.\n2. Does not currently works as a physician, physician assistant, patient navigator and\u002For health system\u002Fadministrative leader in UF and UM affiliated clinics.\n3. Does not self-report having the ability to read and speak English.\n4. Not able to provide informed consent.\n5. Participant is considered a \"vulnerable population\" (pregnant women, neonates, children etc.)","100 Years",{"count":88,"type":20},100,[58],"The goal of this clinical trial is to adapt, implement, and evaluate MyCarePulse and ASCENT patient navigator to overcome barriers to care among patients with cancer.\n\nThe main hypotheses it aims to test are:\n\n* At the patient level, the intervention will result in higher levels of food security, self- efficacy for dietary behaviors, and higher diet quality than standard care.\n* At the provider level, the intervention will be feasible, acceptable, appropriate, and able to enhance individualized care for patient wellness.\n\nResearchers will compare cancer patients receiving the MyCarePulse and ASCENT patient navigator intervention to those receiving standard care, to see if the intervention improves food security, self-efficacy, and diet quality.\n\nPhase 1\n\nPatient Participants will:\n\n* Complete the ASCENT Questionnaire, which is comprised of the following:\n\n  * U.S. Food Security Survey Module (U.S. FSSM)\n  * Patient-Reported Outcomes Measurement Information System (PROMIS-29)\n  * Automated Self-Administered 24-Hour (ASA24®) Dietary Assessment Tool\n* Be assessed using the Veggie Meter instrument\n* Participate in two semi-structured interviews\n\nProvider Participants will:\n\n•Participate in one semi-structured interview\n\nPhase 2\n\nPatient Participants will:\n\n* Participate in ASCENT patient navigator screenings and consultations\n* Complete the ASCENT Questionnaire, which comprises the U.S. FSSM, PROMIS-29, and ASA24®",[92,93,94,95,96,97,98,99,100,101,102,103,104,26],"Cancer","Food Deprivation","Food Habits","Food Selection","Colorectal Cancer","Prostate Cancer","Lung Cancer","Breast Cancer","Gynecologic Cancer","Hematologic Cancer","Skin Cancer","Melanoma","Nutrition Poor",[106,92,107,108,109,110],"Food Insecurity","Food Access","Community-Informed Research","Nutritional Needs","Mixed-Methods","2026-02-19",{"date":113,"type":37},"2026-02-20",{"date":115,"type":37},"2025-12-05",{"date":117,"type":20},"2027-08",{"name":119,"class":44},"University of Florida",1,{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":15,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":133,"briefSummary":134,"conditions":135,"keywords":139,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":154},"100462841","an-exploratory-study-of-arginine-supplementation-and-the-postoperative-immune-response-100462841","NCT05306925","An Exploratory Study of Arginine Supplementation and the Postoperative Immune REsponse","An Exploratory Study of Arginine Supplementation and the Postoperative Immune REsponse (ASPIRE)","ASPIRE","Inclusion Criteria:\n\n* Preterm infants born \\\u003C30 weeks gestation requiring laparotomy\u002Fmajor bowel surgery or diagnosed with necrotising enterocolitis (Modified Bell's Stage II or higher) before discharge\n* Term and near term infants (born\\>35 weeks gestation) requiring laparotomy\u002Fmajor bowel surgery in the first 3 days of life (gastroschisis; major bowel atresias expected to require at least 7 days of PN)\n\nExclusion Criteria:\n\n* Infants who are unlikely to survive because of poor immediate postoperative condition\n* Infants known (or suspected to have) a diagnosis of inborn error of metabolism or serious liver dysfunction\n* Parents who are unable to give informed consent","22 Weeks","44 Weeks",{"count":132,"type":20},48,[58],"ASPIRE is a nutrition study focusing on the effect of arginine supplementation on immune function in postoperative infants.\n\nThe investigators will explore the effect of current intravenous feeding (parenteral nutrition (PN)) formulations and oral arginine supplementation on blood arginine levels and the genes that are involved in body nutrition and fighting infection in babies who have had major bowel surgery or been diagnosed with necrotising enterocolitis. The investigators will undertake an exploratory physiological study across two sites under which are part of a single neonatal partnership. 48 infants will be recruited; 24 preterm infants and 24 term\u002Fnear term infants. 16 of these infants (8 preterm and 8 term\u002Fnear term) will be supplemented with arginine in both oral and parenteral form, 16 infants will receive arginine supplementation in oral form alone and 16 infants will receive standard nutrition with no arginine supplement. The investigators will record nutritional intake and routine biochemical testing data (which includes amino acid levels) collected over the first 30 days post surgery or post NEC diagnosis. The investigators will take blood for analysis at prespecified intervals for RNA sequencing, ammonia and metabolomics. RNA sequencing findings will allow the investigators to describe the effect of arginine on gene activity in postoperative infants\n\nThe investigators hypothesise that arginine supplementation will result in changes in gene expression that are consistent with changes in T-cell function and associated inflammatory pathways.",[136,137,26,138],"Preterm","Surgery","Immune System and Related Disorders",[140,141,142,143,144],"Neonate","Arginine","Postoperative","Immune function","Nutrition","2026-02-17",{"date":147,"type":37},"2026-02-18",{"date":149,"type":37},"2022-04-14",{"date":151,"type":20},"2026-12-31",{"name":153,"class":44},"University of Liverpool",2,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":21,"phases":164,"briefSummary":165,"conditions":166,"keywords":168,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":120},"100502685","development-and-testing-of-nutritional-algorithms-nacho-100502685","NCT05825469","Development and Testing of Nutritional Algorithms (NACHO)","Development and Usability Testing of Nutrition Algorithms for Cancer Health Outcomes (NACHO) and Quality of Life During Cancer Treatment","Inclusion Criteria for Dietitians\u002FOncology clinicians - Have worked with at least 3 patients at the study site who had nutritional challenges\n\nInclusion Criteria for Patient and Family Advisory Council (PFAC) participants\n\n* Current member of adult PFAC\n* \\> 18 years old\n\nInclusion Criteria for Patient participants\n\n* \\> 18 years old\n* Able to speak and read English\n* Completed primary treatment (aim 2b) or actively undergoing treatment (aim 2b and aim 3, exploratory)\n* Access to a device (e.g., computer, tablet, smartphone) through which they can receive and engage with a REDCap link\n\nExclusion Criteria for Patient Participants\n\n• Provider does not recommend",{"count":163,"type":20},130,[58],"The goal of this research study is to develop a nutrition algorithm to optimize nutritional status and improve quality of life during for participants who are completing or have completed cancer treatment.\n\nThe name of the intervention used in this research study is:\n\nNutrition Algorithm for Cancer Health Outcomes (NACHO) (a technology-based platform that houses the algorithms for the person-centered nutrition program)",[104,26,167],"Quality of Life",[169,26,167],"Poor Nutrition","2026-02-03",{"date":172,"type":37},"2026-02-06",{"date":174,"type":20},"2026-09-01",{"date":176,"type":20},"2027-03-31",{"name":178,"class":44},"Dana-Farber Cancer Institute",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":21,"phases":189,"briefSummary":190,"conditions":191,"keywords":194,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":120},"100489652","enhanced-nutritional-optimization-in-lvad-trial-100489652","NCT05655910","Enhanced Nutritional Optimization in LVAD Trial","Enhanced Nutritional Optimization in LVAD (ENOL) Trial","ENOL","Inclusion Criteria:\n\n* age \\>18 years\n* hospitalized\n* undergoing LVAD therapy (enrolled at time of acceptance)\n\nExclusion Criteria:\n\n* intubated\n* congenital heart disease\n* infiltrative cardiomyopathy\n* unable to tolerate oral nutrition\n* surgery expected in \\\u003C5 days",{"count":188,"type":20},50,[58],"The goal of this clinical trial is to assess whether a peri-operative intervention with nutritional immune modulating intervention (Ensure Surgery Immunonutrition shake) has beneficial effects on the complex interplay between gut microbiome, systemic inflammation and malnutrition that is commonly present in advanced heart failure and the adverse events associated with left ventricular assist device (LVAD) placement in hospitalized advanced heart failure patients awaiting LVAD implantation. The main questions it aims to answer are:\n\n* Will pre-surgical supplementation with Ensure Surgery affect gut microbial composition and levels of inflammation among heart failure patients undergoing LVAD implantation?\n* Will pre-surgical supplementation with Ensure Surgery affect post-surgical morbidity (e.g., infections, intensive care unit length of stay (LOS)) and mortality? Participants will be evaluated for malnutrition and will be given Ensure Surgery Immunonutrition shake to drink in the days preceding their LVAD surgery. Blood and stool samples will be collected at prespecified timepoints before and after surgery.\n\nResearchers will compare malnourished participants drinking Ensure Surgery 3\u002Fday with well-nourished participants randomized to drink either 1\u002Fday or 3\u002Fday to see if any of the above supplementation strategies change the gut microbial composition, levels of inflammation, and post-surgical morbidity and mortality.",[192,193,26],"Heart Failure","Gut Microbiome",[195,196,197,198,193],"Left Ventricular Assist Device (LVAD)","Advanced Heart Failure","Mechanical Circulatory Support","Infection","2025-10-30",{"date":201,"type":37},"2025-10-31",{"date":203,"type":37},"2022-09-22",{"date":205,"type":20},"2027-01",{"name":207,"class":44},"Columbia University",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":21,"phases":216,"briefSummary":217,"conditions":218,"keywords":221,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":233,"locationsCount":235},"100508903","push-it-continuing-enteral-feeds-for-tracheostomy-100508903","NCT05906472","PUSH-IT Continuing Enteral Feeds for Tracheostomy","Prevent Unnecessary Surgeon Holds of Ingestions for Tracheostomy (PUSH-IT)","Inclusion Criteria:\n\n* 18 years or older\n* admitted to the intensive care unit (ICU)\n* intubated and require tracheostomy\n\nExclusion Criteria:\n\n* under 18 years\n* unable to obtain informed consent\n* deemed clinically brain dead within 7 days of enrollment\n* transitioned to comfort measures within 7 days of enrollment\n* Pregnant patients\n* Prisoners",{"count":56,"type":20},[58],"The goal of this clinical trial is to evaluate nutrition administration in the time around the tracheostomy in patients with breathing tubes. The main questions it aims to answer are:\n\n* Will continuing nutrition up to the time of surgery (tracheostomy) decrease nutrition interruptions, thereby increasing food intake?\n* Does continuing nutrition up to the time of surgery increase instances of food going into the lungs or lung infections?\n\nResearchers will compare patients who have nutrition withheld 6 hours prior to surgery versus those who receive nutrition up until the time of surgery to see if there are differences in food intake, instances of food entering the lungs or lung infections.",[219,220,26],"Tracheostomy Complication","Critical Illness",[222,223,224,225,226],"tube feed","nil per os","aspiration","pneumonia","nutritional delivery","2025-10-16",{"date":229,"type":37},"2025-10-20",{"date":231,"type":37},"2023-02-06",{"date":151,"type":20},{"name":234,"class":44},"State University of New York at Buffalo",6,{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":15,"minAge":243,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":21,"phases":247,"briefSummary":249,"conditions":250,"keywords":253,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":120},"100497933","phase-4-vitality-in-infants-via-azithromycin-for-neonates-trial-100497933","NCT05763693","Vitality in Infants Via Azithromycin for Neonates Trial","VIVANT","Inclusion Criteria:\n\n* Aged 1-27 days old\n* Birthweight \\\u003C 2500 g and\u002For weight-for-height Z score \\\u003C- 2 standard deviations at enrollment\n* Weigh at least 1500 g at time of enrollment\n* Able to feed orally\n* Family intends to stay in the study area for at least 6 months\n* Written informed consent from at least one caregiver\n* Afebrile\n* Caregiver at least 18 years old\n* No known allergy to macrolides\n* No hepatic failure manifested by neonatal jaundice\n* Not currently an inpatient at the clinic\n* Not being transferred to a hospital for clinical complications\n\nExclusion Criteria:\n\n* Birthweight \\> 2500 g\n* Weigh less than 1500 g at time of enrollment\n* Unable to feed orally\n* Family planning to move within 6 months\n* Mother\u002F caregiver not willing to participate\n* Allergic to macrolides\n* Hepatic failure manifested by neonatal jaundice\n* Currently being seen as an inpatient at the clinic\n* Currently being transferred to a hospital for clinical complications","1 Day","27 Days",{"count":246,"type":20},4000,[248],"PHASE4","Nearly half of child deaths occur during the neonatal period, and 80% of those occur in babies with low birthweight. Although tremendous progress has been made towards reducing under-five mortality globally, declines in neonatal mortality lag behind those observed in older children. Low birthweight babies are at increased risk of poor outcomes compared to those who are term-appropriate for gestational age, including mortality, stunting, and growth failure. Recent evidence has demonstrated that the incidence of wasting and linear growth failure is highest between birth and 3 months of age, substantially earlier than previously thought. Interventions are urgently needed to improve outcomes in low birthweight babies; however, these interventions must not interfere with breastfeeding and thus some well-established interventions used to treat or prevent malnutrition in older children cannot be considered. The investigators recently demonstrated that biannual mass azithromycin distribution reduces all-cause childhood mortality by approximately 25% in infants aged 1-5 months, with stronger effects seen in underweight infants. This study did not include neonates due to the risk of infantile hypertrophic pyloric stenosis (IHPS) that has been hypothesized to be associated with macrolide use during early infancy. However, our study team documented only a single case of IHPS among 21,833 neonates enrolled in a trial of azithromycin versus placebo administered to neonates aged 8-27 days for prevention of infant mortality, documenting no major risk of IHPS associated with azithromycin. Here, the investigators propose an individually randomized trial where participants will receive a single oral dose of azithromycin (administered either during the neontal period or 21 days after enrollment), two does of oral azithromycin spaced 21 days apart, or two doses of placebo to evalute if azithromycin improves nutritional outcome and reduces infectious burden among neonates aged 1-27 days who are either low birthweight (\\\u003C2500 g at birth) or underweight (weight-for-age Z-score \\\u003C -2 at enrollment). The primary outcome will be weight-for-age Z-score at 6 months of age compared between arms. The investigators anticipate that the results of this study will provide definitive evidence on azithromycin as an early intervention for low birthweight\u002Funderweight neonates, who are at the highest risk of adverse outcomes.",[251,252,26],"Neonatal Death","Infectious Disease",[254,255],"Low birth weight","underweight neonates","2025-08-28",{"date":258,"type":37},"2025-08-29",{"date":260,"type":20},"2026-04",{"date":262,"type":20},"2030-04",{"name":264,"class":44},"University of California, San Francisco",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":271,"targetDuration":273,"studyType":274,"phases":4,"briefSummary":275,"conditions":276,"keywords":278,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":120},"100588586","effects-of-enteral-nutrition-content-on-disease-progression-in-sepsis-patients-100588586","NCT06943326","Effects of Enteral Nutrition Content on Disease Progression in Sepsis Patients","Inclusion Criteria:\n\n* Being diagnosed with sepsis and being able to receive enteral nutrition 24 hours after starting treatment in the intensive care unit\n\nExclusion Criteria:\n\n* chronic liver disease, chronic renal failure, active cancer or parenteral nutrition",{"count":272,"type":20},60,"1 Week","OBSERVATIONAL","The aim of this study was to investigate the effects of enteral nutrition content on disease progression in sepsis patients.",[277,26],"Sepsis",[279,280,281],"sepsis","intensive care","nutrition","2025-04-16",{"date":284,"type":37},"2025-04-24",{"date":286,"type":37},"2024-11-01",{"date":288,"type":20},"2025-05-01",{"name":290,"class":44},"Inonu University",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":21,"phases":300,"briefSummary":302,"conditions":303,"keywords":304,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":120},"100468433","phase-2-nutritional-supplementation-in-head-and-neck-cancers-100468433","NCT05379712","Nutritional Supplementation in Head and Neck Cancers","A Randomized Open Label Trial of Multimodal Oral Nutritional Supplementation Versus Standard Care, to Prevent \u002F Attenuate Malnutrition in Patients with Cancers of the Head and Neck Receiving (chemo)-radiotherapy Treatment.","Inclusion Criteria:\n\n1. Patients must have the ability to read, understand, and sign an informed consent and must be willing to comply with study treatment and follow-up.\n2. Male or female\n3. ≥18 years of age\n4. Histopathologically confirmed primary squamous cell carcinoma of the oral cavity and oropharynx, larynx or hypopharynx, who have agreed to receive radical intent radiotherapy as primary treatment or adjuvant treatment post-surgery, with or without platinum chemotherapy\n5. Capable of volitional oral nutritional intake at baseline.\n6. A diagnostic CT image taken with a maximum of 30 days before initiation of radical intent radiotherapy. If the CT scan history in the patient's clinical record does not include a study within this window, a baseline non-contrast enhanced CT abdomen will be conducted.\n7. An Eastern Cooperative Oncology Group Performance Status of ≤ 2\n\nExclusion Criteria:\n\n1. Fed by nasogastric tube, gastrostomy or total parenteral nutrition\n2. Cancer of the nasopharynx, thyroid or salivary gland\n3. Life expectancy \\\u003C6 months.\n4. A known hypersensitivity \u002F allergy to the investigational product or to any ingredient in their formulations (e.g. Milk\u002FLactose, Fish).\n5. Enrolment in any other clinical protocol or investigational study with an interventional agent or assessments that may interfere with study procedures.\n6. Patients with untreated brain metastases (patients with previously resected and\u002For radiated brain metastases without neurologic symptoms are permitted).\n7. Poorly controlled chronic illnesses or other inflammatory diseases (e.g. COPD, uncontrolled non-insulin dependent diabetes, rheumatoid arthritis).\n8. In the investigators' opinion, patients who have medical conditions that could interfere with nutrient metabolism or absorption (e.g., short bowel syndrome, Crohn's disease, etc.)",{"count":299,"type":20},81,[301],"PHASE2","The purpose of this study is to determine whether multimodal nutrition therapy (primary nutrition intervention + adjuvant nutrition therapy) will support patients to optimize their total caloric intake during cancer treatment by measuring the difference in mean cumulative energy intake between the intervention and control group over the duration of cancer treatment.",[62,26,63],[305,65],"Nutritional Support","2025-03-25",{"date":308,"type":37},"2025-03-28",{"date":310,"type":37},"2024-10-25",{"date":312,"type":20},"2026-10",{"name":314,"class":44},"AHS Cancer Control Alberta",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":321,"sex":322,"minAge":323,"maxAge":324,"enrollmentInfo":325,"targetDuration":4,"studyType":21,"phases":326,"briefSummary":327,"conditions":328,"keywords":329,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":120},"100580444","effects-of-metabolic-testing-data-and-education-on-attitudes-and-beliefs-related-to-carbohydrate-intake-in-adolescent-female-athletes-100580444","NCT06837376","Effects of Metabolic Testing Data and Education on Attitudes and Beliefs Related to Carbohydrate Intake in Adolescent Female Athletes","Inclusion Criteria:\n\n1. Females aged between the ages of 13-19 years old\n2. Non-smoker\n3. Currently enrolled in an IMG Academy sport\n4. Willing to fast overnight (10 hours) prior to testing (for metabolic testing group).\n5. Understand the protocol and be able to give verbal and written informed consent for participation as well as obtain parental consent if \\\u003C18 years of age.\n6. Must be fluent in English reading, writing, and speaking.\n7. You are not employed by, or have a parent, guardian, or other immediate family member employed by a company that manufactures any products that compete with any Gatorade product. If you are unsure if a company would be considered a competitor to Gatorade, let the study investigator know the name of the other company and the nature of your relationship to that company before you sign the informed consent\n8. If subject has asthma, they may still participate in but will be required to bring their prescribed inhaler if placed in the metabolic testing group\n\nExclusion Criteria:\n\n1. Expulsion from school for any reason\n2. Leaving the IMG sports team\n3. Pregnant or planning to become pregnant\n4. Participated in any other clinical trial in the past 30 day\n5. Participated in any PepsiCo trial in the past 6 months\n6. Physical injury that would prevent participation in exercise group",true,"FEMALE","13 Years","19 Years",{"count":272,"type":20},[58],"Many studies have consistently shown that females across sports under consume carbohydrate. Registered dietitians working with athletes have also reported female athletes chronically under consume carbohydrate. The primary objective of this study is to compare the effectiveness of education versus education plus interpreted individual metabolic (exercise) testing results to change attitudes and beliefs of female athletes regarding carbohydrate intake. The secondary objective is to assess the effectiveness of the education alone on attitudes and beliefs towards consuming carbohydrate in female athletes.\n\nThe study hypothesis is that education alone will not significantly impact attitudes and beliefs, and that metabolic testing and the interpretation of the individual results will alter attitudes and beliefs toward carbohydrate intake.",[26],[330,331,332,333,334,335,336],"exercise performance","metabolic testing","education","carbohydrate","adolescent","female","athlete","2025-02-14",{"date":339,"type":37},"2025-02-20",{"date":341,"type":37},"2025-02-05",{"date":343,"type":20},"2025-05-15",{"name":345,"class":346},"PepsiCo Global R&D","INDUSTRY",{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":321,"sex":15,"minAge":354,"maxAge":16,"enrollmentInfo":355,"targetDuration":4,"studyType":274,"phases":4,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":154},"100559755","celiac-disease-and-quality-of-life-in-children-and-adolescents-celiaqlife-100559755","NCT06568263","Celiac Disease and Quality of Life in Children and Adolescents (CeliaQLife)","CeliaQLife","Inclusion Criteria:\n\n* eating a regular diet\n\nExclusion Criteria:\n\n\\-","6 Years",{"count":356,"type":20},160,"Celiac disease is a disorder commonly diagnosed during childhood. The treatment is a lifelong gluten-free diet. Both the condition and the diet can influence the children's physical and emotional well-being.\n\nThe main goal of this observational study is to learn about nutritional status in a group of children with celiac disease compared to a group of healthy children.\n\nThe nutritional assessment includes information on diet, biochemical measurement, and body composition. Quality of life will also be assessed.\n\nThe study can contribute to ensure good health and well-being in children on a gluten-free diet.",[359,26,167],"Celiac Disease in Children","2024-08-20",{"date":362,"type":37},"2024-08-23",{"date":364,"type":37},"2024-08-12",{"date":366,"type":20},"2025-12-20",{"name":368,"class":44},"Oslo University Hospital",{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":377,"targetDuration":379,"studyType":274,"phases":4,"briefSummary":380,"conditions":381,"keywords":388,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":120},"100488978","impact-of-very-high-protein-content-enteral-nutrition-formulas-on-critically-ill-multiple-trauma-patients-100488978","NCT05647135","ImpACt of Very High Protein Content Enteral nUtrition Formulas on Critically Ill MUltipLe trAuma paTiEnts","ImpACt of Very High Protein Content Enteral nUtrition Formulas on Protein Metabolism and Residual Gastric Volume in Critically Ill MUltipLe trAuma paTiEnts","ACCUMULATE","Inclusion Criteria:\n\n* Adult patients (\\>18 yrs) admitted to the ICU\n* Multiple trauma (Injury severity score \\> 18)\n* Intubation and mechanical ventilation upon admission in ICU or during the first 24 hours of admission, for at least 48 h\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnant women\n* Patients not intubated or not mechanically ventilated or receiving only non-invasive ventilation\n* Patients with enteral feeding contraindication 48 h after admission\n* Patients with recent gastrointestinal surgical intervention\n* Patients on chronic therapy with corticosteroids",{"count":378,"type":20},70,"8 Weeks","This prospective observational randomized study aims to determine energy, protein intake and gastrointestinal tolerance while using enteral nutrition formulas with very high protein content and enteral nutrition formulas with normal protein content.\n\n* Differences regarding achieving protein and calorie daily targets when using enteral nutrition formulas with different protein content\n* Differences regarding residual gastric volume when using enteral nutrition formulas with different protein content\n* Differences regarding body composition when using enteral nutrition formulas with different protein content",[382,383,26,384,385,386,387],"Metabolism","Trauma","Protein Malnutrition","Gastroparesis","Muscle Loss","Calorie Malnutrition Protein",[389,390,391,392,393,394,395],"enteral nutrition","multiple trauma","energy target","protein target","body composition","gastric residual volume","enteral nutrition intolerance","2024-07-17",{"date":398,"type":37},"2024-07-22",{"date":400,"type":37},"2023-03-01",{"date":402,"type":20},"2024-12-01",{"name":404,"class":44},"Romanian Society for Enteral and Parenteral Nutrition",{"id":406,"slug":407,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":321,"sex":15,"minAge":411,"maxAge":412,"enrollmentInfo":413,"targetDuration":4,"studyType":21,"phases":414,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":4},"100549412","phase-3-enteral-zinc-supplementation-in-very-low-birth-weight-infants-100549412","NCT06433674","Enteral Zinc Supplementation in Very Low Birth Weight Infants","Inclusion Criteria:\n\n1. Birth weight \\\u003C 1500 grams\n2. Infant is tolerating at least 100 ml\u002Fkg\u002Fday of enteral feeds\n3. At least 25wks PMA.\n\nExclusion Criteria:\n\n* Major congenital malformations especially anomaly of the GI tract\n* Major congenital heart disease (i.e.: ductal dependent lesion)\n* Previously diagnosed necrotizing enterocolitis (stage 2 or 3), bowel perforation, or bowel resection\n* Infant who has tolerated ≥100 ml\u002Fkg\u002Fday prior to admission.","25 Weeks","36 Weeks",{"count":188,"type":20},[23],"The goal of this clinical trial is to observe for changes in rate of weight gain in the very low birth weight (VLBW) infants by adding an enteral Zinc supplement of 1 mg\u002Fkg\u002Fday of elemental zinc. The main question it aims to answer:\n\n• Does an enteral Zinc supplement of 1 mg\u002Fkg\u002Fday increase rate of weight gain in VLBW infants Researches will compare the experimental group to a placebo group to see if there is a statistical difference in rate of weight gain between the two groups\n\n* Once the participants have reached 100 ml\u002Fkg\u002Fday of enteral feeds. The participants will be randomized to one of two groups. The treatment group will receive \\~1 mg\u002Fkg\u002Fday of elemental enteral Zinc, and the control group to receive similar amount of enteral sterile water put in a colored syringe. The Zinc Supplement would be Zinc Sulfate. The primary team would otherwise be managing the patient's feeding using our hospital's feeding protocol. As long as the patient is tolerating 100 ml\u002Fkg\u002Fday of enteral feeds, the Zinc Supplement will continue until 36 weeks postmenstrual age (PMA) or hospital discharge, whichever comes first.\n* The participants will have three Zinc levels measured: once prior to Zinc Supplementation, once at around the four week mark, and once at the completion of therapy.",[417,26],"Very Low Birth Weight Infant","2024-06-04",{"date":420,"type":37},"2024-06-06",{"date":422,"type":20},"2024-06-01",{"date":424,"type":20},"2025-07-01",{"name":426,"class":44},"University of Tennessee"]